Ionis Pharmaceuticals has dosed the first subject in the global, randomised Phase III REVEAL trial of investigational ION582.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the global Phase 3 ...

Ivor Washbrook loves climbing trees and singing and dancing with his sisters. He also has a syndrome that will affect his ...

A mum in Monmouth describes her fears about managing her severely disabled son's care needs.

A child with Angelman syndrome – which affects around one in 21,000 births worldwide – will typically begin to show signs of delayed development at around six to 12 months. There are no ...

The firm expects to complete enrolling the REVEAL trial, in which patients will receive the ASO, dubbed ION582, in 2026.

For the Mrozinksy family, the first few months of their 7-month-old son Logan's life have been focused on saving it.

A migrant father who previously got permission from border czar Tom Homan to temporarily remain in the U.S. to care for his disabled kids is now at risk of deportation.

ALBUQUERQUE, N.M. – Troubling video shows Bernalillo County deputies trying to safely disarm two young boys holding a loaded handgun. The sheriff’s office says this is just one example of the ...